William J. Mackillop

Learn More
Adriamycin cytotoxicity and membrane permeability to Adriamycin were studied at elevated temperatures in a drug-sensitive Chinese hamster ovary cell line and in a pleiotropic drug-resistant mutant to determine whether hyperthermia can overcome this form of acquired drug resistance. In drug-sensitive cells Adriamycin cytotoxicity, measured by colony survival(More)
The study was designed to determine which formats for displaying quantities, such as probabilities of treatment risks and benefits, are perceived most accurately and easily by patients. Accuracy and speed of processing were compared for six different presentation formats: pie charts, vertical bars, horizontal bars, numbers, systematic ovals, and random(More)
One hundred cancer patients undergoing active treatment were interviewed to determine how they perceived their illness and how their perceptions compared with those of their attending physicians. Ninety-eight patients recognized that they had cancer and 87 correctly identified the tumour type. Sixty-four of 67 patients with local or regional disease were(More)
To test the identity of human tumour clonogenic cells and stem cells, a procedure was developed to allow quantitation of self-renewal capacity of human ovarian carcinoma clonogenic cells. Primary colonies grown from malignant effusions of 10 patients were disaggregated and replated; secondary colonies were observed to be similar to primary colonies in size,(More)
The effect of temperature on the cytotoxicity of melphalan in a pleiotropic drug-resistant mutant CHO cell line (CHR C5) and in its drug-sensitive parent (Aux B1) was studied in vitro using a clonogenic assay. The cytotoxicity of melphalan was significantly enhanced at elevated but non-lethal temperatures (39-41 degrees C) and hyperthermia potentiated the(More)
One hundred and eighteen doctors who treat pulmonary neoplasms in Ontario were asked how they would wish to be treated if they had non-small cell lung cancer. Four different scenarios were given. The physicians were then asked if they would consent to take part as subjects in one or more clinical trials for which they would be eligible in those situations.(More)
Doctors who treat lung cancer in Ontario were previously asked how they would wish to be managed if they developed non-small cell lung cancer and whether they would consent to participate in six clinical trials for which they might be eligible. The proportion of these expert surrogate patients who would consent to each clinical trial ranged from 11 to 64%.(More)
Seven consecutive ascitic tumors were obtained over a 9-month period from a patient with serous adenocarcinoma of the ovary. The tumor cell populations were analyzed for cellular proliferation (labeling index, agar clonogenicity, and self-renewal capacity), for cell differentiation (cell surface expression of carcinoembryonic antigen and histochemical stain(More)
A method is presented for the description of a heterogeneous cell population with respect to the volume and density of its cellular components, based on computer analysis of the cell-volume spectra of density-gradient fractions. Display programmes were developed to produce either a perspective plot or an isofrequency contour plot ("fingerprint") of the(More)
BACKGROUND Adjuvant chemotherapy (ACT) is known to improve survival in patients with early-stage non-small cell lung cancer. Herein, we describe chemotherapy regimens used, dose modifications, survival, and treatment-related toxicity in the general population. METHODS All cases of non-small cell lung cancer diagnosed in Ontario in the period 2004-2006 who(More)